bioRxiv preprint doi: https://doi.org/10.1101/2020.02.25.965590; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Bacteriophages targeting Acinetobacter baumannii capsule 2 induce antimicrobial resensitization 3 4 Fernando Gordillo Altamirano1*, John H. Forsyth1, Ruzeen Patwa1, Xenia Kostoulias2, Michael Trim1, Dinesh 5 Subedi1, Stuart Archer3, Faye C. Morris2, Cody Oliveira1, Luisa Kielty1, Denis Korneev1, Moira K. O’Bryan1, 6 Trevor J. Lithgow2, Anton Y. Peleg2,4, Jeremy J. Barr1* 7 8 1 School of Biological Sciences, Monash University 9 2 Biomedicine Discovery Institute and Department of Microbiology, Monash University 10 3 Monash Bioinformatics Platform, Faculty of Medicine, Nursing and Health Sciences, Monash University 11 4 Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University 12 13 *Corresponding authors 14 Fernando Gordillo Altamirano
[email protected] 15 Jeremy J. Barr
[email protected] 16 School of Biological Sciences, Monash University 17 25 Rainforest Walk, 18 Clayton, 3800, VIC 19 Australia 20 21 Abstract 22 Carbapenem-resistant Acinetobacter baumannii is responsible for frequent, hard-to-treat and often fatal 23 healthcare-associated infections. Phage therapy, the use of viruses that infect and kill bacteria, is an approach 24 gaining significant clinical interest to combat antibiotic-resistant infections. However, a major limitation is that 25 bacteria can develop resistance against phages. Here, we isolated phages with activity against a panel of A.